30-day average of 20 articles ยท scale โ100 to +100
Across 20 scored articles from Oct 17 to Nov 15, 2026 (UTC),
the average sentiment of AbbVie news is Bullish (+51)
on a scale from โ100 to +100.
That is about the same as the previous 30 days (+53).
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion.
Bullish +62
AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
AI-generated analysis
Key insights
๐ AbbVie shares surged over 23% year-to-date, outperforming the S&P 500's roughly 13% gain as investors assess its transition strategy.
๐ Skyrizi and Rinvoq drove immunology revenue to $8.79 billion (up 15.1%), with Skyrizi up 24.4% and Rinvoq up 24.5%, offsetting a 35.9% decline in Humira.
๐ง The neuroscience portfolio delivered strong growth, increasing revenue by 20.3% to $3.23 billion in the second quarter.
๐ค AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion to bolster its immunology pipeline with late-stage candidate zumilokibart.
๐ฐ The company reported total second-quarter revenue of $16.99 billion (up 10.2%) and adjusted diluted EPS rose 22.9% on a reported basis.
โ ๏ธ Management expects the Apogee acquisition to have a $0.14 per share dilutive impact on 2026 adjusted EPS, alongside an unfavorable $0.58-per-share impact from acquired IPR&D expenses.
๐ AbbVie's forward P/E is approximately 16.4x, significantly lower than its trailing P/E of 74.88x due to non-recurring acquisition-related items affecting reported earnings.
๐ฎ The company expects 2026 adjusted diluted EPS between $13.87 and $14.07, following a revision to its July outlook.
๐ Humira revenue fell 35.9% to $756 million in the second quarter as AbbVie continues its portfolio transition away from the aging blockbuster.
๐ The Apogee acquisition is expected to close in the third quarter of 2026, adding clinical-stage immunology assets to the pipeline.
๐ Bullish signals
๐AbbVie shares surged over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain.
๐Skyrizi and Rinvoq generated combined immunology revenue of $8.79 billion (up 15.1%), with individual growth rates of 24.4% and 24.5% respectively, effectively offsetting the decline in Humira.
๐ง The neuroscience portfolio demonstrated robust expansion with revenue increasing 20.3% to $3.23 billion in the second quarter.
๐ฐTotal company revenue increased 10.2% on a reported basis to $16.99 billion in the second quarter, while adjusted diluted EPS rose 22.9%.
๐ Risk factors
๐Humira revenue fell 35.9% to $756 million in the second quarter as the company continues its transition away from the aging blockbuster.
โ ๏ธThe acquisition of Apogee Therapeutics for approximately $10.9 billion will have a dilutive impact on 2026 adjusted EPS, including an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the deal itself.
๐AbbVie's trailing P/E ratio is nearly 75x (74.88x), significantly higher than its forward P/E of 16.4x, indicating that reported earnings are currently depressed by significant acquisition-related and other specified items.
Article
AbbVie (NYSE: ABBV) has delivered strong returns in the first half of 2026, with shares surging over 23% year-to-date, significantly outperforming the broader market's roughly 13% gain. The company is currently trading at a forward P/E of approximately 16.4x, which analysts view as reasonable given its growth trajectory, though this contrasts sharply with its trailing P/E of nearly 75x due to significant acquisition-related and other specified items affecting reported earnings.
The core investment thesis for AbbVie centers on its ability to successfully transition away from the declining blockbuster Humira, which saw revenue fall 35.9% in the second quarter to $756 million. This decline has been effectively offset by robust growth in its newer immunology franchises: Skyrizi generated $5.505 billion (up 24.4%) and Rinvoq generated $2.53 billion (up 24.5%), bringing total global net revenue from the immunology portfolio to $8.79 billion, a 15.1% increase.
Beyond immunology, AbbVie's neuroscience portfolio showed particular strength with revenue increasing 20.3% to $3.23 billion in the second quarter. The company is also executing a major strategic expansion by acquiring Apogee Therapeutics for approximately $10.9 billion to add late-stage clinical assets like zumilokibart, expected to close in the third quarter of 2026. However, this acquisition and ongoing pipeline investment will have a dilutive impact on adjusted EPS, with management expecting an unfavorable $0.58-per-share impact from acquired IPR&D expenses and an additional $0.14 per share dilution from the Apogee deal itself.
Sector and industry come from company profile data. Sentiment is the AI score of the news articles on this page, averaged per day. Not investment advice.
AbbVie Inc. shares rallied to trade near their 52-week high of $267.47, reaching approximately $263.52 on September 21, 2026, following the announcement of a multi-year collaboration with Iambic. This partnership leverages artificial intelligence to accelerate small molecule drug discovery across AbbVie's key therapeutic areas, including immunology, neuroscience, and oncology.
The strategic deal aims to identify first-in-class and best-in-class therapies while utilizing digital tools to compress discovery timelines. By integrating Iambic's AI-driven platform, AbbVie intends to deepen its pipeline in these critical franchises and sustain its growth trajectory as it transitions away from its legacy Humira franchise.
Financially, the company reported strong double-digit revenue growth in Q2 2026, driven by the scaling of newer assets like Skyrizi and Rinvoq. This positive financial backdrop supports AbbVie's status as a dividend payer with a yield around 2.59%, reinforcing investor confidence in the balance between growth investment and shareholder returns.
Market data indicates heightened interest in the stock, with trading volume reaching 8.18 million shares compared to an average daily volume of 4.73 million. The market is currently pricing AbbVie based on a combination of its growing pipeline, ongoing dividend payments, and new AI-driven discovery initiatives.
๐ Stock trades near $267.47 high after Iambic AI drug discovery deal.
๐ค AI partnership accelerates small molecule discovery across immunology and oncology.
๐ฐ Q2 2026 revenue grew double-digits as Humira transition continues.
๐ Skyrizi and Rinvoq assets scale successfully to support growth.
๐ต Maintains ~2.59% dividend yield for income-focused investors.
๐ AbbVie stock gained value to trade near its 52-week high of $267.47 following the announcement of a multi-year AI drug discovery collaboration with Iambic.
๐ค The partnership applies artificial intelligence to small molecule drug discovery across immunology, neuroscience, and oncology to accelerate therapy identification.
๐ AbbVie aims to use digital tools from the deal to compress discovery timelines and deepen its pipeline in key therapeutic franchises.
๐ฐ The company reported strong double-digit revenue growth in Q2 2026 as it transitions beyond its legacy Humira franchise.
๐ New assets Skyrizi and Rinvoq are scaling successfully, supporting the company's growth trajectory alongside the new AI initiative.
๐ต AbbVie maintains a dividend yield of approximately 2.59%, reinforcing its appeal to investors seeking both growth and income.
๐ Trading volume surged to 8.18 million shares on September 21, 2026, indicating heightened investor interest in the AI collaboration news.
Bullish Signals
Stock rallied near 52-week high of $267.47 after Iambic AI deal.
Q2 2026 revenue grew double-digits as Skyrizi and Rinvoq scaled.
Iambic partnership accelerates first-in-class small molecule therapy discovery.
Digital tools compress R&D timelines to improve pipeline efficiency.
Market cap $466.34B reflects confidence in strategic direction.
Bullish Signals
AbbVie stock rallied to trade near its 52-week high of $267.47 following the announcement of a multi-year AI drug discovery collaboration with Iambic.
The company reported strong double-digit revenue growth in Q2 2026, demonstrating successful scaling of newer assets like Skyrizi and Rinvoq.
The partnership with Iambic aims to accelerate the identification of first-in-class and best-in-class small molecule therapies across key therapeutic areas.
AbbVie is utilizing digital tools from the collaboration to compress discovery timelines, potentially improving efficiency in its R&D pipeline.
The stock traded at $263.52 with a market capitalization of approximately $466.34 billion, reflecting strong market confidence in the company's strategic direction.
AbbVie Inc. stock closed at USD 263.96 on September 18, 2026, showing a negligible 0.02% decline while trading near recent highs. The company maintains its status as an income-oriented large-cap pharmaceutical name with a declared quarterly dividend of USD 1.73 per share and an ex-dividend date set for October 15, 2026.
Valuation metrics indicate that AbbVie trades at a trailing price-to-earnings multiple of 74.6 times, which is approximately 18% above its five-year median, though the forward multiple is cited at 16.2 times based on next year's earnings expectations. Analyst sentiment remains broadly positive, with 32 of 39 tracked analysts maintaining a bullish stance on the stock.
The company's pipeline progress and commercial milestones, particularly in its migraine franchise, are expected to support growth following the loss of exclusivity on legacy products like Humira. Over the trailing twelve months, AbbVie shares have gained 18.91%, outpacing broader market benchmarks as investors weigh dividend income against elevated valuation expectations.
Market data from various platforms highlights that while a small minority of analysts remain cautious, the consensus view is that AbbVie's earnings and cash flows remain attractive in the medium term. Future quarterly results and clinical updates will be closely scrutinized to confirm whether pipeline contributions can sustain the current premium valuation.
๐ Stock closed at $263.96 with negligible decline and slight after-hours gain.
๐ฐ Quarterly dividend of $1.73/share implies forward yield of about 2.6%.
๐ Trading at trailing P/E of 74.6x, 18% above five-year median.
๐ Analyst sentiment is strongly bullish with 32 of 39 ratings as Buy.
๐ Migraine franchise milestone adds growth to post-Humira portfolio.
๐ AbbVie Inc. stock closed at USD 263.96 on September 18, 2026, with a negligible 0.02% decline and an after-hours indication of USD 264.18.
๐ฐ The company announced a quarterly dividend of USD 1.73 per share with an ex-dividend date of October 15, 2026, implying a forward yield of about 2.6%.
๐ Valuation metrics show AbbVie trading at a trailing P/E of 74.6x (18% above its five-year median) and a forward P/E of 16.2x based on next year's earnings.
๐ Analyst sentiment is strongly bullish, with 32 of 39 tracked analysts rating the stock as Buy and only 3.1% as Sell.
๐ AbbVie's migraine franchise recently achieved a notable regulatory and commercial milestone, adding growth to its post-Humira portfolio.
๐ Stock performance over the trailing twelve months shows a gain of 18.91%, outpacing many broader market benchmarks.
๐ Investors note that AbbVie trades at an elevated valuation level where future quarterly results will be critical to sustaining the premium multiple.
Bullish Signals
Stock gained 18.91% over trailing twelve months.
32/39 analysts rate shares Buy for pipeline growth.
Declared quarterly dividend of USD 1.73 per share.
Risk Factors
P/E multiple of 74.6x is 18% above five-year median.
Pipeline must sustain premium after legacy product exclusivity loss.
Bullish Signals
AbbVie Inc. stock has delivered solid total returns over the last year, gaining 18.91% over the trailing twelve months and outpacing broader market benchmarks.
The company maintains a strong analyst consensus with 32 of 39 tracked analysts classifying shares as Buy, betting that post-Humira pipeline growth will accelerate.
AbbVie recently achieved a notable regulatory and commercial milestone for its migraine franchise, adding another growth leg to its portfolio of immunology and oncology assets.
The declared quarterly dividend of USD 1.73 per share reinforces the company's profile as an attractive income-oriented large-cap pharmaceutical name.
Risk Factors
AbbVie trades at a trailing price-to-earnings multiple of 74.6 times, which is roughly 18% above its five-year median, suggesting elevated valuation expectations.
The stock faces scrutiny as investors assess whether pipeline contributions can sustain the current premium valuation given the loss of exclusivity on legacy products.
AbbVie Inc. stock traded at USD 263.52 on September 19, 2026, holding near its 52-week high of USD 267.47 with a market capitalization of USD 466.34 billion. The company reported strong second-quarter financial results, posting adjusted earnings per share of USD 2.03 compared to USD 0.52 a year earlier, while revenue increased by 10.16 percent to reach USD 16.99 billion.
Analyst consensus for AbbVie stands at USD 277.31, representing a potential upside of approximately 5.64 percent from the current trading price, with ratings generally leaning towards Buy. However, valuation metrics present a mixed picture, as the GF Value model suggests the stock is trading at a 19.6 percent premium to its fair value of USD 220.69.
The pharmaceutical giant's shares saw a session volume of 8.18 million shares on September 19, with intraday activity reaching a high of USD 266.29. The next quarterly earnings report is scheduled for release on October 23, 2026, keeping investor attention focused on future guidance and performance trends.
๐ Stock closed at USD 263.52 below 52-week high of USD 267.47.
๐ฐ Q2 revenue surged to USD 16.99 billion, up 10.16% year-over-year.
๐ Adjusted EPS jumped to USD 2.03 from USD 0.52 last year.
๐ฏ Analyst consensus target of USD 277.31 implies 5.64% upside.
โ๏ธ GF Value suggests fair price of USD 220.69 vs market price.
๐ AbbVie stock closed at USD 263.52 on September 19, 2026, trading just below its 52-week high of USD 267.47.
๐ฐ Second-quarter revenue surged to USD 16.99 billion, marking a 10.16 percent year-over-year increase.
๐ Adjusted earnings per share jumped significantly to USD 2.03 in the second quarter compared to USD 0.52 last year.
๐ฏ Analyst consensus price target is set at USD 277.31, implying roughly 5.64 percent upside from current levels.
โ๏ธ Valuation models indicate overvaluation, with GF Value suggesting a fair price of USD 220.69 versus the market price of USD 264.02.
๐ Trading volume reached 8.18 million shares on September 19, reflecting active investor interest near yearly highs.
๐๏ธ The next earnings report is scheduled for release on October 23, 2026.
Bullish Signals
Revenue grew 10.16% to USD 16.99 billion.
Adjusted EPS tripled year-over-year to USD 2.03.
Stock trades near 52-week high of USD 267.47.
Analyst target implies 5.64% upside potential.
Risk Factors
Valuation shows 19.6% premium to fair value.
Stock at 52-week highs limits upside.
Bullish Signals
AbbVie reported robust second-quarter revenue growth of 10.16 percent to USD 16.99 billion, demonstrating strong top-line performance.
Adjusted earnings per share more than tripled year-over-year to USD 2.03, highlighting significant profitability improvement.
The stock is trading near its 52-week high of USD 267.47 with a market cap of USD 466.34 billion, indicating strong investor confidence.
Analyst consensus price target of USD 277.31 suggests potential upside of 5.64 percent from current trading levels.
Risk Factors
Valuation metrics suggest the stock is overvalued, with GF Value indicating a 19.6 percent premium to its calculated fair value of USD 220.69.
The stock price has reached near-52-week highs, which may limit immediate upside potential and increase sensitivity to any earnings miss.
AbbVie Inc. (ABBV) is a global biopharmaceutical company with a current dividend yield of 2.59% based on a $6.83 annual payout and a share price of $263.37. The company has increased its dividend for over 11 consecutive years, demonstrating a long history of commitment to shareholder returns despite recent earnings volatility.
The article highlights a significant concern regarding ABBV's trailing payout ratio of 189.7%, which indicates that current earnings alone do not cover the dividend payment. Analysts and investors are advised to scrutinize this metric, noting that free cash flow coverage and forward earnings estimates may provide a more accurate picture of dividend safety than trailing EPS in this specific context.
Historically, ABBV has shown strong dividend growth with a compound annual growth rate (CAGR) of 12.5% from 2013 to 2025. While the current yield is slightly above its five-year average, the elevated payout ratio creates pressure on sustainability if earnings do not expand or if the company faces setbacks in its blockbuster drug portfolio.
AbbVie's diversified therapeutic portfolio includes major products like HUMIRA, SKYRIZI, and RINVOQ across immunology, oncology, and neurology. The stock exhibits low volatility with a beta of 0.281, making it attractive to income investors seeking price stability, though the high payout ratio remains the primary risk factor for long-term dividend sustainability.
๐ ABBV offers a 2.59% dividend yield with $6.83 annual payout per share.
๐ Trailing payout ratio is 189.7%, exceeding current earnings coverage.
๐ Dividend growth streak spans over 11 years at a 12.5% CAGR.
๐ก๏ธ Stock shows low volatility with a beta of 0.281 for stability.
๐ Revenue driven by HUMIRA, SKYRIZI, and RINVOQ blockbuster drugs.
๐ ABBV offers a current dividend yield of 2.59% with an annual payout of $6.83 per share and a quarterly payment of $1.73.
๐ The company's trailing payout ratio stands at 189.7%, indicating that earnings alone do not currently cover the dividend payments.
๐ ABBV has maintained a streak of dividend growth for over 11 consecutive years, with a historical CAGR of 12.5% from 2013 to 2025.
๐ก๏ธ The stock displays low volatility with a beta of 0.281, appealing to income investors who prioritize price stability over capital gains.
๐ AbbVie's revenue is driven by a diversified portfolio including blockbuster drugs like HUMIRA, SKYRIZI, and RINVOQ across multiple therapeutic areas.
๐ The next ex-dividend date for ABBV is scheduled for October 15, 2026.
Bullish Signals
Dividend increased 11+ years.
Yield 2.59% vs 2.25% avg.
Beta 0.281 for stability.
Risk Factors
Payout ratio is 189.7%, risking dividend sustainability if earnings drop.
Dividend safety relies on free cash flow, not trailing EPS.
Bullish Signals
AbbVie has increased its dividend for over 11 consecutive years, demonstrating a strong track record of commitment to shareholder returns.
The current dividend yield of 2.59% is slightly above the company's five-year average of 2.25%, offering attractive income relative to historical norms.
ABBV exhibits low market volatility with a beta of 0.281, making it suitable for investors seeking price stability alongside dividend income.
Risk Factors
The trailing payout ratio is 189.7%, meaning current earnings alone do not cover the dividend, creating potential sustainability risks if earnings decline.
Investors must rely on free cash flow or forward earnings estimates rather than trailing EPS to accurately assess the safety of ABBV's dividend payments.
The article argues that AbbVie (NYSE: ABBV) is the superior dividend investment compared to Pfizer, citing a longer history of dividend growth and stronger revenue expansion. While Pfizer offers a higher current yield at 6.1%, AbbVie provides a more sustainable profile with a Dividend King status, having increased its quarterly dividend for 53 consecutive years.
AbbVie successfully navigated the expiration of its blockbuster drug Humira by pivoting to home-grown immunology assets, Skyrizi and Rinvoq. By 2025, these new drugs generated over $25 billion in combined annual sales, effectively replacing lost revenue and pushing total company revenue to record highs. This strategic transition allowed the company to return to mid- to high-single-digit top-line growth without a permanent structural hit.
In contrast, Pfizer faces significant patent cliffs between 2026 and 2028, exposing roughly $17 billion to $18 billion in annual revenue from core blockbusters like Eliquis and Ibrance. Although AbbVie carries more total debt at roughly $62 billion, its leverage is manageable due to strong cash flows from new products, whereas Pfizer's debt-to-equity ratio is over three times higher as it pays down obligations amidst legacy drug erosion.
Financial performance highlights include AbbVie's second-quarter sales of $16.9 billion, up 10.2% year over year, driven by Skyrizi ($5.5 billion) and Rinvoq ($2.52 billion). The company also recently acquired Apogee Therapeutics for $10.9 billion to expand its atopic dermatitis portfolio, further solidifying its growth trajectory against Pfizer's acquisition of Metsera for weight-loss therapies.
๐ AbbVie outperforms Pfizer with superior dividend growth and revenue expansion.
๐ฐ AbbVie raised quarterly dividend 5.5% to $1.73 for 53 consecutive years.
๐ Skyrizi and Rinvoq replaced Humira, generating over $25 billion in sales.
๐ Q2 sales rose 10.2% year-over-year to $16.9 billion driven by immunology.
๐ AbbVie is identified as the smarter dividend buy over Pfizer due to a superior track record of dividend growth and revenue expansion.
๐ฐ AbbVie has increased its quarterly dividend for 53 consecutive years, earning Dividend King status, with a recent 5.5% raise to $1.73 per share.
๐ Pfizer faces greater exposure to patent exclusivity loss between 2026 and 2028, risking roughly $17 billion to $18 billion in annual revenue from core blockbusters.
๐ AbbVie successfully replaced Humira revenue with home-grown assets Skyrizi and Rinvoq, which combined generated over $25 billion in sales by 2025.
๐ Q2 earnings showed AbbVie sales rising 10.2% year over year to $16.9 billion, driven primarily by its immunology portfolio.
๐ธ Pfizer's debt-to-equity level is more than three times that of AbbVie, creating greater pressure on cash-flow conversion as legacy drugs lose market share.
๐ค AbbVie is executing a multi-year portfolio pivot with recent acquisitions like Apogee Therapeutics ($10.9 billion) to capture new therapeutic areas.
๐ Over the past decade, AbbVie's revenue grew by more than 138% compared to Pfizer's growth of just over 18%.
Bullish Signals
Dividend King status with 53 consecutive years of increases.
Skyrizi and Rinvoq generated over $25B annual sales.
Q2 sales reached $16.9B, up 10.2% year-over-year.
Returned to mid- to high-single-digit top-line growth.
Acquired Apogee Therapeutics for $10.9 billion.
Risk Factors
Long-term debt is $62B vs Pfizer's $32.6B.
Bullish Signals
AbbVie has increased its quarterly dividend for 53 consecutive years, achieving Dividend King status with a recent 5.5% raise to $1.73 per share.
The company successfully navigated the Humira patent cliff by developing Skyrizi and Rinvoq, which combined generated over $25 billion in annual sales by 2025.
Second-quarter sales reached $16.9 billion, a 10.2% year-over-year increase driven by strong performance from its immunology drugs.
AbbVie returned to mid- to high-single-digit top-line growth after bridging the immunology drop-off without taking a permanent structural hit.
The company acquired Apogee Therapeutics for $10.9 billion to gain access to promising atopic dermatitis therapy zumilokibart.
Risk Factors
AbbVie carries more long-term debt, roughly $62 billion as of the second quarter, compared to Pfizer's $32.6 billion.
AbbVie (NYSE: ABBV) is positioned ahead of its July 31 Q2 earnings report with strong momentum driven by two blockbuster immunology drugs, Skyrizi and Rinvoq. These products combined generated $6.6 billion in revenue during the first quarter of 2026, effectively replacing Humira as the company's primary growth engines. Management has raised full-year guidance for both drugs to $21.6 billion and $10.2 billion respectively, signaling confidence that they will generate nearly $32 billion in annual sales.
The stock currently trades at a forward P/E of 18x with a PEG ratio of 0.43, presenting a valuation below the S&P 500 average while offering low volatility with a beta of 0.28. Wall Street consensus targets the stock at $267.79, slightly above the current price of $265.52, supported by 16 Buy and 8 Strong Buy ratings. The company recently increased its quarterly dividend by 5.5% to $1.73 per share, lifting full-year adjusted EPS guidance to a range of $14.08 to $14.28.
AbbVie has successfully navigated the patent cliff that rivals Merck and Pfizer are currently facing or will face in the coming years. While Humira revenue continues to decline due to biosimilar competition, the company's overall trajectory is defined by the rapid expansion of its newer portfolio. The upcoming earnings report on July 31 is expected to confirm whether these new products can sustain growth and support further increases to full-year guidance.
๐ AbbVie trades at forward P/E of 18x with PEG ratio of 0.43.
๐ฐ Dividend raised 5.5% to $1.73; full-year EPS guidance lifted to $14.28.
๐ Skyrizi and Rinvoq generated $6.6B Q1 revenue with strong growth.
๐ก๏ธ AbbVie crossed biosimilar patent cliff, positioning ahead of competitors.
๐ฏ Consensus price target is $267.79 with 24 Buy/Strong Buy ratings.
๐ AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43, offering growth prospects at a valuation below the S&P 500 average.
๐ฐ The company raised its quarterly dividend by 5.5% to $1.73 per share and lifted full-year adjusted EPS guidance to $14.08-$14.28.
๐ Skyrizi and Rinvoq combined generated $6.6 billion in Q1 2026 revenue, with Skyrizi growing 30.9% YoY and Rinvoq growing 23.3% YoY.
๐ Management raised full-year sales guidance for Skyrizi to $21.6 billion and for Rinvoq to $10.2 billion.
๐ก๏ธ AbbVie has already crossed the biosimilar patent cliff that Merck faces in 2028, positioning it ahead of key competitors.
๐ The stock exhibits low volatility with a beta of 0.28 compared to the broader market's higher risk profile.
๐ฏ Wall Street consensus price target is $267.79 across 16 Buy and 8 Strong Buy ratings from analysts.
๐ผ Immunology revenue grew 16.4% in Q1 as the two new drugs replaced Humira as the primary growth drivers.
Bullish Signals
Trades at 18x forward P/E with 0.43 PEG ratio.
Raised quarterly dividend 5.5% to $1.73/share.
Skyrizi and Rinvoq generated $6.6B Q1 revenue.
Raised full-year sales guidance for key drugs.
Beta of 0.28 offers low volatility growth.
Bullish Signals
AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43, offering attractive valuation relative to growth prospects and below the S&P 500 average.
The company increased its quarterly dividend by 5.5% to $1.73 per share and raised full-year adjusted EPS guidance to $14.08-$14.28, signaling strong income coverage.
Skyrizi and Rinvoq combined generated $6.6 billion in Q1 2026 revenue, with Skyrizi growing 30.9% YoY and Rinvoq growing 23.3% YoY.
Management raised full-year sales guidance for Skyrizi to $21.6 billion and for Rinvoq to $10.2 billion, projecting nearly $32 billion in annual sales.
The stock has a beta of 0.28, providing low volatility compared to the broader market while maintaining significant growth momentum.
Wall Street consensus price target is $267.79 across 16 Buy and 8 Strong Buy ratings, indicating strong analyst confidence in the current valuation.
AbbVie (ABBV) has established itself as a major cash-return engine, returning approximately $62 billion to shareholders over the last five years through dividends and buybacks. This total represents about 13.4% of the company's current market value and ranks as the 25th largest among all U.S. companies. The substantial capital returns are fueled by a highly profitable immunology portfolio that has successfully replaced older revenue streams with a new generation of blockbuster drugs.
The company's commercial durability is driven by SKYRIZI, which saw sales surge 24% to $5.5 billion in the most recent quarter, and RINVOQ, which climbed 24% to over $2.5 billion. These immunology products generated $18.21 billion in free cash flow over the last twelve months, supporting a history of potent shareholder returns including a +161% total stock return over five years, nearly double the S&P 500's performance.
Management maintains confidence in its growth drivers, forecasting SKYRIZI to generate $21.7 billion in global revenues for the full year. However, investors are debating whether high cash returns come at the expense of reinvestment, noting a price-to-earnings multiple of 72.9 and potential risks from an increasingly crowded development landscape in immunology where competitive inroads could alter the company's calculus.
๐ AbbVie returned $62B to shareholders over the last five years.
๐ฐ Company generated $18.21B in free cash flow trailing twelve months.
๐ SKYRIZI sales surged 24% to $5.5 billion in the latest quarter.
โ ๏ธ Stock trades at a price-to-earnings multiple of 72.9, raising valuation concerns.
๐ผ AbbVie acquired Apogee Therapeutics to bolster its immunology portfolio.
๐ AbbVie returned $62 billion to shareholders over the last five years, ranking as the 25th largest cash returner among U.S. companies.
๐ฐ The company generated $18.21 billion in free cash flow over the trailing twelve months, fueling its robust capital return machine.
๐ SKYRIZI sales surged 24% to $5.5 billion in the most recent quarter, while RINVOQ sales climbed 24% to over $2.5 billion.
๐ AbbVie stock delivered a +161% total return over the past five years, significantly outperforming the S&P 500's +82% gain.
๐ฏ Management forecasts SKYRIZI will generate $21.7 billion in global revenues for the full year, supporting dividend commitments.
โ ๏ธ The stock trades at a price-to-earnings multiple of 72.9, prompting debate over whether shares have become too expensive relative to growth.
๐ฌ Analysts probe risks regarding an increasingly crowded development landscape for AbbVie's key immunology drugs.
๐ผ Management recently announced a deal for Apogee Therapeutics to bolster its leading immunology portfolio.
Bullish Signals
AbbVie returned $62 billion to shareholders over the last five years, ranking as the 25th largest cash returner among all U.S. companies.
The company generated $18.21 billion in free cash flow over the trailing twelve months, demonstrating a highly profitable business model.
SKYRIZI sales surged 24% to $5.5 billion in the most recent quarter, while RINVOQ sales climbed 24% to over $2.5 billion.
Holding AbbVie stock produced a +161% total return over the past five years, nearly doubling the S&P 500's return.
Management forecasts SKYRIZI will generate $21.7 billion in global revenues for the full year, indicating strong commercial durability.
Risk Factors
The stock trades at a price-to-earnings multiple of 72.9, prompting debate over whether shares have become too expensive.
Analysts on the latest earnings call probed risks regarding an increasingly crowded development landscape for key drugs.
Investors face the risk that unexpected competitive inroads in immunology could quickly alter the company's cash return calculus.
AbbVie (NYSE:ABBV) has demonstrated strong financial performance in the second quarter, reporting revenue of nearly $17 billion, a 10.2% increase year-over-year. The company's growth is primarily driven by its blockbuster biologic drugs, with Skyrizi generating $5.5 billion and Rinvoq surpassing $2.5 billion in sales during the period.
Management has raised full-year earnings per share (EPS) guidance to a range of $13.87 to $14.07, reflecting confidence in the company's pipeline and execution capabilities. Analyst Piper Sandler recently increased its price target on AbbVie shares to $303 while maintaining an Overweight rating, citing the firm's robust long-term outlook.
Strategic initiatives are poised to further accelerate growth, including a $10.9 billion agreement with Apogee Therapeutics and the upcoming launch of Skyrizi as a subcutaneous formulation for Crohn's disease. The company continues to prioritize shareholder returns, having raised its annualized dividend to $6.92 from $6.56 in the prior year.
Looking ahead to 2027, AbbVie aims to achieve a share price of $325, which would imply a forward P/E multiple of approximately 23x. This target relies on sustained beat streaks, successful pipeline delivery, and favorable macroeconomic conditions to support the valuation expansion required to reach this level.
๐ AbbVie Q2 revenue rose 10.2% to nearly $17 billion.
๐ Skyrizi and Rinvoq sales grew 24% and 23.7% respectively.
๐ค AbbVie signed a $10.9 billion deal with Apogee Therapeutics.
๐ Management raised full-year EPS guidance to $13.87-$14.07.
๐ฐ Annualized dividend increased to $6.92 per share.
๐ AbbVie reported Q2 revenue of nearly $17 billion, representing a 10.2% increase compared to the prior year.
๐ Skyrizi sales reached $5.5 billion in the quarter, marking a significant 24% growth rate.
๐ Rinvoq sales exceeded $2.5 billion, achieving a robust 23.7% increase during the same period.
๐ Management raised full-year EPS guidance to a range of $13.87 to $14.07.
๐ค AbbVie signed a $10.9 billion deal with Apogee Therapeutics to expand its portfolio.
๐ The company is preparing to launch Skyrizi as a subcutaneous injection for Crohn's disease.
๐ฐ AbbVie increased its annualized dividend to $6.92, up from $6.56 in the previous year.
๐ Piper Sandler raised its price target on AbbVie shares to $303 with an Overweight rating.
๐ฏ Analysts project a potential share price of $325 by 2027 if growth targets are met.
๐ The current forward P/E multiple is approximately 18x, below the implied 23x at the $325 target.
Bullish Signals
Q2 revenue hit nearly $17B, up 10.2% YoY.
Skyrizi sales reached $5.5B, growing 24%.
Rinvoq sales surpassed $2.5B, up 23.7%.
Raised full-year EPS guidance to $13.87-$14.07.
Piper Sandler raised price target to $303.
Bullish Signals
AbbVie reported Q2 revenue of nearly $17 billion, a 10.2% increase year-over-year.
Skyrizi sales reached $5.5 billion in the quarter, growing by 24%.
Rinvoq sales surpassed $2.5 billion, achieving a 23.7% increase.
Management raised full-year EPS guidance to a range of $13.87 to $14.07.
Piper Sandler raised its price target on AbbVie shares to $303 with an Overweight rating.
The company signed a $10.9 billion deal with Apogee Therapeutics.
AbbVie increased its annualized dividend to $6.92, up from $6.56 in the prior year.
AbbVie (ABBV) reported strong financial performance in the second quarter of 2026, with total net revenues reaching $16.99 billion, a 10.2% increase year over year. This growth was driven primarily by its immunology and neuroscience franchises, specifically Skyrizi and Rinvoq, which generated a combined $8.03 billion in revenue for the quarter. These figures represent a successful transition away from Humira, which contributed only $756 million after losing US exclusivity to biosimilars.
The company demonstrated robust profitability with an adjusted gross margin of 84.7% and an adjusted operating margin of 48.3%. AbbVie declared a quarterly dividend of $1.73 per share, maintaining its status as a Dividend Aristocrat while managing substantial debt from the Allergan acquisition. Management also raised full-year 2026 revenue guidance by approximately $300 million to roughly $67.6 billion.
Strategically, AbbVie agreed to acquire Apogee Therapeutics for an equity value of roughly $10.9 billion to deepen its immunology franchise with a new extended half-life IL-13 antibody. The company also secured patent settlements extending US generic competition for Rinvoq until April 2037 and is pursuing regulatory approvals for new indications in Skyrizi and Rinvoq, including vitiligo and alopecia areata.
๐ Q2 2026 revenue hit $16.99B, up 10.2% operationally.
๐ Skyrizi and Rinvoq generated $8.03B combined quarterly revenue.
๐ก๏ธ US exclusivity for Rinvoq extended until April 2037.
๐ค Acquired Apogee Therapeutics for roughly $10.9 billion cash.
๐ฏ Raised full-year 2026 revenue guidance to ~$67.6B.
๐ AbbVie reported Q2 2026 total net revenues of $16.99 billion, representing a 10.2% operational increase year over year.
๐ Skyrizi and Rinvoq combined generated $8.03 billion in revenue for the quarter, significantly outpacing Humira's contribution of $756 million.
๐ Humira revenue fell 36.1% operationally to $756 million following the loss of US exclusivity in 2023.
๐ก๏ธ AbbVie settled patent challenges with generic filers, extending US exclusivity for Rinvoq until April 2037.
๐ฐ The company declared a quarterly dividend of $1.73 per share, annualizing to a yield of approximately 2.8% at the reported price.
๐ค AbbVie agreed to acquire Apogee Therapeutics for roughly $10.9 billion in cash to expand its immunology pipeline.
๐ Adjusted diluted EPS rose 22.9% year over year to $3.65, reflecting strong underlying cash economics despite GAAP charges.
๐ฌ Skyrizi revenue reached approximately $5.5 billion in the quarter, up around 24% operationally from the prior year.
๐ Rinvoq passed $2.5 billion in quarterly revenue, growing 23.7% operationally as it expands into new indications.
๐ฏ AbbVie raised full-year 2026 revenue guidance by about $300 million to approximately $67.6 billion.
โ๏ธ The company maintained an adjusted operating margin of 48.3%, absorbing a 1.7 percentage point impact from acquired in-process R&D.
๐ AbbVie trimmed adjusted diluted EPS guidance slightly to reflect anticipated dilution from the Apogee acquisition transaction.
Bullish Signals
Revenue grew 10.2% YoY to $16.99B in Q2 2026.
Skyrizi and Rinvoq generated $8.03B, exceeding Humira's peak.
Adjusted diluted EPS rose 22.9% YoY to $3.65.
Raised full-year 2026 guidance by ~$300M to $67.6B.
Acquired Apogee Therapeutics for $10.9B to expand immunology.
Risk Factors
Humira revenue fell 36.1% to $756M in Q2 2026 due to biosimilar exclusivity loss.
EPS guidance trimmed slightly reflecting dilution from Apogee acquisition transaction.
Substantial Allergan debt competes with buybacks for capital allocation.
Bullish Signals
Total net revenues grew 10.2% year over year to $16.99 billion in Q2 2026, demonstrating successful portfolio transition.
Skyrizi and Rinvoq generated a combined $8.03 billion in revenue for the quarter, comfortably exceeding Humira's peak performance.
Adjusted diluted EPS increased 22.9% year over year to $3.65, highlighting strong underlying cash flow generation.
The company raised full-year 2026 revenue guidance by approximately $300 million to roughly $67.6 billion.
AbbVie secured patent settlements extending US exclusivity for Rinvoq until April 2037, providing a decade-long planning horizon.
Skyrizi alone reached about $5.5 billion in quarterly revenue, up around 24% operationally from the prior year.
AbbVie agreed to acquire Apogee Therapeutics for roughly $10.9 billion to deepen its immunology franchise with a next-generation IL-13 antibody.
The company maintains an adjusted operating margin of 48.3%, reflecting the high-margin nature of its branded pharmaceutical business.
AbbVie declared a quarterly dividend of $1.73 per share, continuing its track record as a Dividend Aristocrat since inception.
Risk Factors
Humira revenue fell 36.1% operationally to $756 million in Q2 2026 following the loss of US exclusivity to biosimilars.
AbbVie trimmed adjusted diluted EPS guidance slightly to reflect anticipated dilution from the Apogee acquisition transaction.
The company carries substantial debt originating from the 2020 Allergan acquisition, which competes with buybacks for capital allocation.
This article presents a comparative investment analysis between pharmaceutical giants AbbVie (ABBV) and Bristol-Myers Squibb (BMY), evaluating their growth potential, financial performance, and risk profiles for investors targeting 2026. The author concludes that AbbVie is the superior pick due to its focused operational strategy, faster growth trajectory, and high-yielding dividend, positioning it as a stronger long-term investment compared to Bristol-Myers Squibb.
AbbVie reported Fiscal Year 2025 revenues of approximately $61.2 billion, representing an 8.6% year-over-year increase driven by the expansion of newer drug labels that offset erosion from legacy products. The company is successfully transitioning away from its dependence on Humira as biosimilar competition subsides, with its neuroscience portfolio accelerating growth and prospects looking promising following the recent patent cliff for its flagship immunology drug.
In contrast, Bristol-Myers Squibb saw a slight revenue decline of 0.2% to $48.2 billion in FY 2025, though it achieved a net income recovery of approximately $7.1 billion largely due to one-time charges. The company faces significant headwinds including expected market exclusivity losses for blockbuster drugs like Eliquis and Opdivo, global pricing restrictions, and dependence on new product launches to sustain growth in its oncology and cardiovascular segments.
The analysis highlights that while Bristol-Myers Squibb trades at a lower Forward P/E ratio suggesting slower growth expectations, AbbVie offers more enticing value through its dividend yield and improved outlook. The author notes that AbbVie recently raised its full-year guidance for the second time this year, reinforcing its positive momentum despite broader industry challenges like drug pricing reforms under the Inflation Reduction Act.
๐ Abbvie FY2025 revenue rose 8.6% to $61.2 billion.
๐ฐ Bristol-Myers Squibb revenue dipped slightly but net income recovered.
๐งฌ Abbvie reduces Humira reliance while neuroscience portfolio accelerates.
โ ๏ธ Bristol-Myers Squibb risks revenue decline from Eliquis and Opdivo exclusivity losses.
๐ Author favors Abbvie for growth, yield, and focused strategy.
๐ AbbVie reported Fiscal Year 2025 revenues of $61.2 billion, an 8.6% increase driven by newer drug labels offsetting legacy product erosion.
๐ฐ Bristol-Myers Squibb recorded a slight revenue decrease to $48.2 billion in FY 2025 but recovered net income to approximately $7.1 billion via one-time charges.
๐งฌ AbbVie is transitioning away from Humira dependence as biosimilar competition mostly passes, with its neuroscience portfolio accelerating growth.
โ ๏ธ Bristol-Myers Squibb faces substantial revenue decline risks due to expected market exclusivity losses for blockbuster drugs Eliquis and Opdivo.
๐ AbbVie recently raised its full-year outlook for the second time this year, signaling strong operational momentum.
๐ธ Both companies offer consistent dividends and stable cash flows, making them attractive to income-seeking investors in the healthcare sector.
๐ The author favors AbbVie over Bristol-Myers Squibb due to its focused strategy, faster growth rate, and higher dividend yield.
๐ Bristol-Myers Squibb trades at a lower Forward P/E ratio than AbbVie, reflecting market expectations of slower future growth.
โ๏ธ Both companies face industry-wide risks including patent expirations, competition from major rivals like Pfizer and Merck, and potential pricing pressures from the Inflation Reduction Act.
Patent expirations on key immunology drugs create ongoing revenue risks.
Rising competition from rivals like Pfizer threatens specialty medicine market share.
Inflation Reduction Act pricing pressures may impact future profitability.
Global reimbursement restrictions limit pricing flexibility and compress margins.
Clinical trial setbacks or regulatory delays risk next-generation pipeline growth.
Bullish Signals
AbbVie achieved an impressive 8.6% revenue growth in FY 2025 to reach $61.2 billion, driven by the successful expansion of newer drug labels.
The company has successfully navigated the Humira patent cliff with biosimilar competition mostly past, allowing its neuroscience portfolio to accelerate growth.
AbbVie recently raised its full-year financial outlook for the second time this year, demonstrating strong management confidence and operational execution.
AbbVie offers one of the most enticing dividends in the healthcare sector, providing significant value to income-focused investors.
The company maintains a focused operation strategy that is delivering better results compared to peers with more diversified but slower-growing portfolios.
Risk Factors
AbbVie faces ongoing risks from patent expirations on key immunology drugs and rising competition in the specialty medicine market against rivals like Pfizer.
The company may be impacted by potential pricing pressures resulting from government regulations under the Inflation Reduction Act.
Bristol-Myers Squibb contends with global pricing and reimbursement restrictions that limit its pricing flexibility and could compress margins.
The company faces long-term growth risks if there are setbacks in clinical trials or regulatory delays for its next-generation pipeline products.
Cantor Fitzgerald has raised its price target for AbbVie (NYSE: ABBV) from $265 to $285, maintaining an overweight rating. This follows a mixed landscape of recent analyst actions, including JPMorgan Chase increasing its target to $280 and DZ Bank upgrading the stock to a strong buy, while Wall Street Zen downgraded its rating to 'buy' and Citigroup kept a neutral stance.
The company reported strong financial results for the quarter ended July 31, with earnings per share of $3.65 beating the consensus estimate of $3.61. Revenue reached $16.99 billion, surpassing analyst expectations of $16.80 billion and representing a 10.2% year-over-year increase. The business achieved a net margin of 9.80%, though it recorded a negative return on equity of 466.39%.
AbbVie has set its Q3 2026 earnings guidance between $3.84 and $3.88 per share, with analysts averaging an expectation of $14.12 EPS for the current fiscal year. The company also declared a quarterly dividend of $1.73 payable on August 14th to shareholders of record as of July 15th, resulting in an annualized yield of 2.8% and a payout ratio of 195.48%. Institutional ownership remains high at 70.23%, with several hedge funds increasing their stakes during the second quarter.
๐ Cantor Fitzgerald raised AbbVie price target to $285.
๐ Q2 earnings beat estimates at $3.65 per share.
๐ฐ Revenue reached $16.99 billion with 10.2% growth.
๐ฏ Q3 guidance set between $3.84 and $3.88 EPS.
๐ต Dividend of $1.73 payable August 14th.
๐ Cantor Fitzgerald raised its price target for AbbVie from $265 to $285 while maintaining an overweight rating.
๐ The company reported Q2 earnings of $3.65 per share, beating the consensus estimate of $3.61 by $0.04.
๐ฐ Revenue for the quarter reached $16.99 billion, exceeding analyst estimates of $16.80 billion.
๐ Year-over-year revenue growth was 10.2%, driven by strong performance across therapeutic areas.
๐ฏ AbbVie provided Q3 2026 earnings guidance ranging from $3.84 to $3.88 per share.
๐ต A quarterly dividend of $1.73 will be paid on August 14th with an ex-dividend date of July 15th.
๐ The stock carries a negative return on equity of -466.39% for the reported quarter.
๐ฆ Institutional ownership stands at 70.23%, with several hedge funds increasing their holdings in Q2.
๐ Analyst consensus rating is 'Moderate Buy' with an average price target of $271.48.
๐ฌ AbbVie focuses on complex chronic conditions across immunology, oncology, neuroscience, and other areas.
Bullish Signals
Cantor Fitzgerald raised price target to $285.
AbbVie beat earnings with $3.65 EPS vs $3.61 consensus.
Revenue of $16.99B exceeded estimates of $16.80B.
Company achieved 10.2% year-over-year revenue increase.
Major banks like JPMorgan Chase issued upgrades.
Risk Factors
Negative ROE of -466.39% indicates significant leverage or accounting adjustments.
Dividend payout ratio of 195.48% exceeds current quarterly earnings.
Bullish Signals
Cantor Fitzgerald increased its price target to $285, signaling strong confidence in the company's near-term prospects.
AbbVie beat earnings expectations with $3.65 EPS compared to the consensus of $3.61.
Revenue of $16.99 billion exceeded analyst estimates of $16.80 billion, demonstrating solid top-line execution.
The company achieved a 10.2% year-over-year revenue increase, indicating sustained growth momentum.
Multiple major banks including JPMorgan Chase and DZ Bank have issued upgrades or maintained overweight ratings.
The board declared a $1.73 quarterly dividend, providing a 2.8% annualized yield to shareholders.
Several hedge funds, including ACT Advisors and Willner & Heller, increased their stakes during the second quarter.
Risk Factors
AbbVie reported a negative return on equity of -466.39%, indicating significant leverage or accounting adjustments affecting equity metrics.
The dividend payout ratio is 195.48%, which exceeds 100% and suggests the company is paying out more than its current quarterly earnings.
AbbVie (NYSE: ABBV) is highlighted as a compelling investment opportunity ahead of its July 31 Q2 earnings report, driven by strong financial metrics and successful product transitions. The company trades at a forward P/E of 18x with a PEG ratio of 0.43 and a low beta of 0.28, offering a 2.62% dividend yield that recently increased by 5.5% to $1.73 per share.
The core growth strategy relies on the blockbuster immunology drugs Skyrizi and Rinvoq, which combined generated $6.6 billion in Q1 revenue. Skyrizi sales reached $4.48 billion (up 30.9% YoY) while Rinvoq added $2.12 billion (up 23.3%), effectively replacing the declining Humira franchise. Management has raised full-year guidance for both drugs, projecting nearly $32 billion in combined annual sales.
AbbVie's financial performance significantly outpaces peers like Pfizer and Merck over the last five years, with a 164% gain compared to Pfizer's decline. The company successfully navigated the biosimilar competition that threatens Merck's Keytruda franchise, positioning itself as a leader in income generation and growth with low market volatility.
๐ Trades at 18x forward P/E with 0.28 beta for low volatility.
๐ฐ Dividend raised 5.5% to $1.73/share yielding 2.62%.
๐ Skyrizi and Rinvoq generated $6.6B combined Q1 revenue.
๐ EPS guidance raised to $14.08-$14.28 ahead of July report.
๐ก๏ธ New drugs projected to generate nearly $32B annually.
๐ AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43 and a beta of 0.28, indicating low volatility relative to the broader market.
๐ฐ The quarterly dividend was raised 5.5% to $1.73 per share, resulting in an annualized yield of 2.62%.
๐ Skyrizi and Rinvoq combined generated $6.6 billion in Q1 revenue, with Skyrizi alone reaching $4.48 billion.
๐ Management raised full-year EPS guidance to a range of $14.08 to $14.28 ahead of the July 31 earnings report.
๐ฌ Skyrizi sales grew 30.9% year-over-year while Rinvoq sales increased 23.3% in the first quarter.
๐ก๏ธ The company has successfully transitioned away from Humira, with new drugs projected to generate nearly $32 billion annually.
๐ AbbVie delivered a 164% five-year return, significantly outperforming Pfizer's negative 23% return over the same period.
๐ Wall Street consensus target price is set at $267.79 with 16 Buy and 8 Strong Buy ratings from analysts.
โ๏ธ AbbVie offers a combination of income, growth, and low volatility compared to peers facing patent cliffs or biosimilar erosion.
Bullish Signals
PEG ratio of 0.43 suggests undervaluation relative to earnings growth.
Quarterly dividend raised 5.5% to $1.73, signaling strong cash flow.
Skyrizi and Rinvoq generated $6.6 billion in Q1 revenue.
Management raised full-year guidance for Skyrizi ($21.6B) and Rinvoq ($10.2B).
Stock achieved 164% five-year gain, vastly outperforming Pfizer's -23% return.
Bullish Signals
AbbVie trades at a PEG ratio of 0.43, suggesting the stock is undervalued relative to its earnings growth rate.
The company raised its quarterly dividend by 5.5% to $1.73, signaling strong cash flow and commitment to shareholder returns.
Skyrizi and Rinvoq combined generated $6.6 billion in Q1 revenue, demonstrating robust demand for the new growth engines.
Management raised full-year guidance for both Skyrizi ($21.6B) and Rinvoq ($10.2B), indicating confidence in future sales.
AbbVie achieved a 164% five-year gain, vastly outperforming competitor Pfizer which saw a -23% return over the same period.
The stock has a low beta of 0.28, providing downside protection and lower volatility compared to the S&P 500 average.
Analyst consensus target price of $267.79 is slightly above the current trading price of $265.52, reflecting positive sentiment.
AbbVie has successfully navigated the biosimilar valley that Merck is currently facing with its Keytruda franchise.
AbbVie (ABBV) stock has delivered a significant 40% return over the last twelve months, trading near its 52-week high as investors assess whether its premium valuation leaves room for future growth. The company's momentum is driven by strong operational efficiency and a successful pivot in its immunology franchise, which remains robust despite biosimilar competition affecting its legacy drug Humira.
Financial metrics highlight AbbVie's strength with an operating margin of 33% compared to the S&P 500 median of 18.4%, and an operating cash flow margin of 34% versus the market average of 22%. Recent quarterly sales demonstrate this growth, with Skyrizi revenue surging 29% to $4.5 billion and Rinvoq sales increasing 20% to $2.1 billion.
Despite these fundamentals, AbbVie trades at a substantial premium with a price-to-earnings multiple of 126.3 against an S&P 500 median of 24.2, and a price-to-sales multiple of 7.3 versus 3.3 for the broader market. Management has lowered its 2026 adjusted earnings per share guidance to a range of $13.90 to $14.10 from a prior forecast of $14.20, setting a critical test for investors regarding execution and valuation justification.
The article notes that while the immunology space is crowded with intense competition, AbbVie's current products are leading. Future performance will depend on whether the company can meet its revised earnings targets to sustain its high valuation in a competitive environment.
โ ๏ธ Intense competition risks the premium valuation narrative.
๐ฏ Execution against revised 2026 guidance is key.
๐ ABBV stock gained 40% over the last twelve months and is trading near its 52-week high.
๐ฐ Operating margin reached 33%, significantly outperforming the S&P 500 median of 18.4%.
๐ต Operating cash flow margin hit 34%, well above the market average of 22%.
๐งฌ Skyrizi sales surged 29% to $4.5 billion in the most recent quarter.
๐ฌ Rinvoq sales grew 20% to $2.1 billion, reinforcing the immunology franchise's strength.
๐ New data shows a Crohn's disease combination therapy could double endoscopic remission rates.
๐ธ P/E multiple stands at 126.3x, a stark premium to the S&P 500 median of 24.2x.
๐ Management lowered its 2026 EPS guidance range to $13.90-$14.10 from a prior forecast of $14.20.
โ ๏ธ Intense competition in immunology and oncology poses risks to the growth narrative supporting the premium valuation.
๐ฏ Investors are watching execution against the revised 2026 guidance as the primary test for the business engine.
Bullish Signals
40% stock return over last twelve months.
33% operating margin vs S&P 500 median of 18.4%.
34% operating cash flow margin vs market average of 22%.
Skyrizi sales surged 29% to $4.5 billion.
Rinvoq sales grew 20% to $2.1 billion.
Risk Factors
P/E multiple of 126.3x is massive premium to S&P 500 median of 24.2x.
Management lowered 2026 adjusted EPS guidance from $14.20 to $13.90-$14.10 range.
Immunology and oncology sectors are crowded fields with relentless competitor development pace.
Competitor breakthrough or clinical setback could challenge growth narrative supporting premium valuation.
Bullish Signals
AbbVie achieved a 40% stock return over the last twelve months, demonstrating strong market performance.
The company's operating margin of 33% crushes the S&P 500 median of 18.4%, indicating superior efficiency.
Operating cash flow margin of 34% significantly exceeds the market average of 22%.
Skyrizi sales surged 29% to $4.5 billion, showing strong growth in a key blockbuster drug.
Rinvoq sales grew 20% to $2.1 billion, confirming continued expansion in the immunology portfolio.
Recent clinical data suggests a combination therapy for Crohn's disease could double endoscopic remission rates compared to monotherapy.
The company has successfully pivoted its immunology franchise to new blockbusters as Humira faces biosimilar competition.
Risk Factors
AbbVie trades at a P/E multiple of 126.3x, which is a massive premium to the S&P 500 median of 24.2x.
Management lowered its 2026 adjusted EPS guidance from $14.20 to a range of $13.90-$14.10.
The immunology and oncology sectors are described as crowded fields with relentless development pace from competitors.
A competitor's breakthrough or a clinical setback for a key pipeline asset could challenge the growth narrative supporting the current premium valuation.
AbbVie Inc. (NYSE: ABBV) shares rose 1.4% to $256.80 following a price target upgrade from Canaccord Genuity, which raised its target from $273.00 to $282.00 while maintaining a buy rating. The stock reached an intraday high of $258.38 with trading volume declining 38% from the daily average. This move follows a series of positive analyst actions throughout the quarter, including upgrades and target price increases from JPMorgan Chase, Piper Sandler, Guggenheim, DZ Bank, and Citigroup.
Institutional investors have significantly increased their stakes in AbbVie during the fourth quarter. Major holders include Vanguard Group, which grew its position by 1.7% to own over $41 billion worth of shares, and State Street Corp, which raised its stake by 1.4%. Geode Capital Management boosted holdings by 10.4%, while Bank of America and Norges Bank also added new positions or increased existing ones, reflecting strong institutional confidence in the biopharmaceutical giant.
Financially, AbbVie reported Q1 earnings of $2.65 per share, beating consensus estimates of $2.59, with revenue reaching $15 billion against expectations of $14.72 billion. Revenue grew 12.4% year-over-year, though the company posted a negative return on equity of 576.45% and a high dividend payout ratio of 340.89%. Analysts project full-year EPS of $14.18, and the stock trades above its 50-day and 200-day moving averages with a market cap of $457.78 billion.
The company focuses on complex chronic conditions through its portfolio in immunology, oncology, neuroscience, virology, and women's health. AbbVie recently announced a quarterly dividend of $1.73 per share payable on August 14th for shareholders of record on July 15th, offering an annualized yield of 2.7%. The stock currently carries a PEG ratio of 0.85 and is rated as a 'Moderate Buy' by MarketBeat with an average target price of $268.10.
๐ Shares rose 1.4% after Canaccord raised target to $282.
๐ JPMorgan upgraded to 'overweight' with $280 price target.
๐ Piper Sandler set new objective at $298.
๐ฐ Q1 revenue hit $15B, beating estimates by 12.4%.
๐ธ Quarterly dividend of $1.73 offers 2.7% yield.
๐ AbbVie shares rose 1.4% to $256.80 after Canaccord Genuity raised its price target from $273.00 to $282.00 with a buy rating.
๐ JPMorgan Chase upgraded the stock to 'overweight' and increased its target price from $260.00 to $280.00 on July 9th.
๐ Piper Sandler restated an 'overweight' rating with a new price objective of $298.00 in a June 23rd report.
๐ฆ Institutional ownership remains strong at 70.23%, with Vanguard Group increasing its stake by 1.7% to hold over $41 billion worth of shares.
๐ Trading volume declined 38% from the average daily volume of 7,082,242 shares during the recent session.
๐ฐ AbbVie reported Q1 revenue of $15 billion, beating analyst estimates of $14.72 billion and growing 12.4% year-over-year.
๐ The company posted earnings per share of $2.65, surpassing the consensus estimate of $2.59 by $0.06.
๐ธ AbbVie announced a quarterly dividend of $1.73 per share with an annualized yield of 2.7% payable on August 14th.
๐ The stock trades at a PEG ratio of 0.85 and a price-to-earnings ratio of 127.64 as of the latest data.
๐ฌ AbbVie's product portfolio spans immunology, oncology, neuroscience, virology, and women's health therapeutic areas.
๐ Analysts project full-year EPS of $14.18 for the current fiscal year based on current consensus estimates.
๐ข Geode Capital Management LLC boosted its holdings by 10.4% in the fourth quarter to own over $10 billion worth of stock.
Bullish Signals
Canaccord raised target to $282.00 with buy rating.
JPMorgan upgraded to overweight, raising target to $280.00.
Piper Sandler set highest target at $298.00.
Guggenheim upgraded to buy, raising target to $261.00.
DZ Bank upgraded to strong-buy in late April.
Citigroup raised target from $230.00 to $260.00.
Vanguard added 3 million shares, increasing stake by 1.7%.
State Street holdings rose 1.4% to $18.5 billion.
Geode Capital boosted position by 10.4% with 4M shares.
Bank of America increased stake by 1.4% with 360k shares.
AbbVie beat Q1 earnings with $2.65 EPS vs $2.59.
Risk Factors
Dividend payout ratio is 340.89%, exceeding earnings.
Bullish Signals
Canaccord Genuity raised its price target from $273.00 to $282.00 and maintained a buy rating, driving immediate share price appreciation.
JPMorgan Chase upgraded AbbVie to 'overweight' and increased its target price by $20.00 to $280.00 in late July.
Piper Sandler issued a new price objective of $298.00, the highest among recent analyst targets mentioned.
Guggenheim upgraded its price objective from $249.00 to $261.00 and assigned a 'buy' rating in early July.
DZ Bank upgraded its rating from 'hold' to 'strong-buy' in late April, indicating sustained institutional interest.
Citigroup increased its target price from $230.00 to $260.00 despite maintaining a neutral rating.
Vanguard Group increased its stake by 1.7% in the fourth quarter, adding over 3 million shares to its portfolio.
State Street Corp raised its holdings by 1.4%, increasing its position value to approximately $18.5 billion.
Geode Capital Management LLC significantly boosted its position by 10.4%, acquiring over 4 million additional shares.
Bank of America increased its stake by 1.4% in the fourth quarter, adding nearly 360,000 shares to its holdings.
AbbVie beat Q1 earnings estimates with $2.65 EPS versus a consensus of $2.59, demonstrating operational strength.
Revenue growth of 12.4% year-over-year to $15 billion indicates successful commercialization of its therapeutic portfolio.
Risk Factors
The dividend payout ratio is extremely high at 340.89%, suggesting the company is paying out more in dividends than its current earnings support.
AbbVie (NYSE: ABBV) stock received a price target boost from Canaccord Genuity, which raised its objective from $273.00 to $282.00 while maintaining a 'buy' rating, suggesting potential upside of 9.81% from current levels. This follows a series of positive analyst actions in July and early August, including Bank of America raising its target to $276.00 with a 'buy' rating on July 10th, JPMorgan increasing its objective to $280.00 with an 'overweight' rating on July 9th, and BMO Capital Markets lifting its target to $300.00 with an 'outperform' rating on July 13th.
The company recently reported strong quarterly financial results released on April 29th, beating consensus estimates for both earnings per share and revenue. AbbVie posted $2.65 in EPS compared to the expected $2.59, driven by revenue of $15 billion which exceeded the $14.72 billion estimate. The quarter saw a 12.4% year-over-year revenue increase, with analysts projecting full-year earnings of $14.18 per share.
Institutional ownership remains significant at 70.23%, with several hedge funds and wealth management firms increasing their stakes in the fourth quarter. Notable activity includes Imprint Wealth LLC boosting its position by 56.2% to own 125 shares, Legacy Wealth Managment LLC ID growing its holding by 115.9% to 136 shares, and new positions taken by Litman Gregory Wealth Management LLC and IFC & Insurance Marketing Inc., indicating continued institutional interest in the biopharmaceutical giant.
๐ Analysts raised price targets to $276โ$300 with strong buy ratings.
๐ฐ Q2 earnings beat estimates at $2.65 per share on $15B revenue.
๐ฎ Full-year earnings projected at $14.18 per share based on trends.
๐ฆ Institutional ownership reached 70.23% with major hedge fund increases.
๐งฌ Company focuses on immunology, oncology, and neuroscience therapeutic areas.
๐ Canaccord Genuity raised its price target on AbbVie from $273.00 to $282.00, citing a 'buy' rating and potential upside of 9.81%.
๐ Bank of America increased its target to $276.00 with a 'buy' rating, while JPMorgan boosted its objective to $280.00 with an 'overweight' rating.
๐ฐ BMO Capital Markets raised its price target to $300.00 and assigned an 'outperform' rating on July 13th.
๐ HSBC reaffirmed a 'buy' rating with a $300.00 price target, contributing to a consensus 'Moderate Buy' rating across analysts.
๐ต AbbVie reported Q2 earnings of $2.65 per share, beating the consensus estimate of $2.59 by $0.06.
๐ Revenue reached $15 billion for the quarter, surpassing the $14.72 billion consensus and growing 12.4% year-over-year.
๐ฎ Analysts project full-year earnings of $14.18 per share based on current market data and company performance trends.
๐ฆ Institutional ownership stands at 70.23%, with hedge funds like Imprint Wealth LLC increasing positions by over 56% in Q4.
๐งฌ The company focuses on complex chronic conditions across immunology, oncology, neuroscience, virology, and women's health therapeutic areas.
๐ AbbVie is headquartered in North Chicago, Illinois, operating as a global research-driven biopharmaceutical entity spun off from Abbott Laboratories.
Bullish Signals
Canaccord raised target to $282.00 (9.81% upside).
Bank of America set target at $276.00.
JPMorgan boosted objective to $280.00.
BMO Capital Markets raised target to $300.00.
AbbVie beat earnings with $2.65 EPS vs $2.59.
Revenue of $15 billion exceeded estimates of $14.72B.
Revenue grew 12.4% year-over-year.
Institutions increased holdings; Imprint up 56.2%, Legacy up 115.9%.
Bullish Signals
Canaccord Genuity raised its price target to $282.00, indicating a 9.81% upside potential from current levels.
Bank of America increased its price target to $276.00 and maintained a 'buy' rating on the stock.
JPMorgan Chase boosted its price objective to $280.00 with an 'overweight' rating, signaling strong analyst confidence.
BMO Capital Markets raised its target to $300.00 and assigned an 'outperform' rating, reflecting positive outlook.
AbbVie beat quarterly earnings expectations with $2.65 EPS versus the consensus of $2.59.
Revenue of $15 billion exceeded analyst estimates of $14.72 billion, demonstrating strong top-line growth.
The company achieved a 12.4% year-over-year revenue increase, highlighting robust business expansion.
Institutional investors increased holdings in Q4, with Imprint Wealth LLC boosting its stake by 56.2% and Legacy Wealth Managment LLC ID growing its position by 115.9%.
AbbVie Inc. (NYSE: ABBV) is highlighted as one of the top 12 stock recommendations generated by ChatGPT, based on criteria including historical performance and economic resilience. The article contextualizes this recommendation within a volatile 2025 market environment driven by trade wars, noting that while broad indices have declined year-to-date, AI adoption could drive future rallies.
The core financial news for AbbVie comes from its first-quarter fiscal 2025 results, which exceeded expectations with total net revenues of $13.3 billion, representing a 9.8% operational growth. The company delivered adjusted diluted earnings per share (EPS) of $2.46, surpassing analyst guidance by 10 cents and raising its full-year EPS guidance to a range of $12.09 to $12.29.
Following the strong earnings report, Wall Street sentiment remains positive, with Morgan Stanley raising its price target from $241 to $250 per share while maintaining an Overweight rating. Additionally, AbbVie received regulatory approval for RINVOQ (upadacitinib) for treating giant cell arthritis in adults, a development supported by recent European Commission authorization.
Analyst consensus currently rates ABBV as a Buy with an average projected upside of nearly 7%, and data from Q4 2024 shows that 85 prominent hedge funds hold stakes in the company. Despite these positive fundamentals, the article notes that ChatGPT ranked AbbVie 11th among its top picks, suggesting the AI model favors high-growth AI stocks over established pharmaceuticals for maximum returns.
๐ ChatGPT ranks AbbVie 11th in top 12 stock recommendations.
๐ฐ Q1 fiscal 2025 revenue hit $13.3 billion, up 9.8%.
๐ Adjusted EPS of $2.46 beat guidance; full-year raised to $12.09-$12.29.
๐ฅ FDA approved RINVOQ for giant cell arthritis in adults.
๐ Morgan Stanley raised price target to $250 with Overweight rating.
๐ AbbVie is included in a list of top 12 stock recommendations generated by ChatGPT based on historical trends and macroeconomic resilience.
๐ฐ Q1 fiscal 2025 net revenues reached $13.3 billion, marking a 9.8% operational increase from the prior year.
๐ The company reported adjusted diluted EPS of $2.46, beating guidance by 10 cents and raising full-year guidance to $12.09-$12.29.
๐ฅ AbbVie secured FDA approval for RINVOQ (upadacitinib) for treating giant cell arthritis in adults following European Commission authorization.
๐ Morgan Stanley raised its price target from $241 to $250 per share while maintaining an Overweight rating on the stock.
๐ค Wall Street analysts maintain a consensus Buy rating with an average projected share price upside of nearly 7%.
๐ฆ Insider Monkey data indicates that 85 prominent hedge funds held stakes in AbbVie as of Q4 2024.
๐ ChatGPT ranked AbbVie 11th among its top 12 picks, favoring AI stocks for higher potential returns despite ABBV's solid performance.
Bullish Signals
Q1 net revenues hit $13.3 billion with 9.8% operational growth.
Adjusted diluted EPS reached $2.46, beating guidance by 10 cents.
Morgan Stanley raised price target to $250 per share.
Full-year adjusted diluted EPS guidance raised to $12.09-$12.29.
FDA approved RINVOQ for giant cell arthritis in adults.
Bullish Signals
AbbVie reported Q1 fiscal 2025 net revenues of $13.3 billion, a 9.8% operational growth that exceeded market expectations.
The company delivered adjusted diluted EPS of $2.46, which was 10 cents above its own guidance midpoint.
Morgan Stanley increased its price target from $241 to $250 per share following the earnings beat.
AbbVie successfully raised its full-year adjusted diluted EPS guidance range to $12.09-$12.29.
The company received FDA approval for RINVOQ (upadacitinib) for treating giant cell arthritis in adults, expanding its therapeutic portfolio.
Wall Street analysts hold a consensus Buy rating with an average projected upside of nearly 7%.
Andra AP fonden significantly increased its stake in AbbVie Inc. (NYSE: ABBV) by 44.2% during the first quarter, acquiring an additional 86,969 shares to bring its total holding to 283,811 shares valued at $61.7 million. This investment makes AbbVie the fund's 18th largest position, representing approximately 0.8% of its total portfolio. Several other institutional investors, including Bank of Jackson Hole Trust and Hardin Capital Partners LLC, also added to their positions in the fourth quarter.
Analyst sentiment remains broadly positive with major firms raising price targets for AbbVie stock. Piper Sandler reaffirmed an overweight rating with a $298 target, while Cantor Fitzgerald, JPMorgan Chase, Citigroup, and UBS Group all increased their price objectives between $240 and $280. The consensus average target price stands at $267.67 based on ratings from MarketBeat.
AbbVie recently reported strong quarterly financial results with revenue of $15 billion, beating analyst expectations of $14.72 billion by 1.9%. The company posted earnings per share of $2.65, surpassing the consensus estimate of $2.59, and achieved a year-over-year revenue growth of 12.4%. Additionally, the company announced a quarterly dividend of $1.73 per share payable on August 14th to stockholders of record as of July 15th.
๐ Andra AP fonden increased AbbVie holdings by 44.2% to $61.7 million.
๐ฏ Analysts raised price targets, with Piper Sandler at $298.00.
The article compares AbbVie (ABBV) and Baxter International (BAX), concluding that while both recently displayed a 'golden cross' technical signal, only AbbVie represents a viable option for income-focused retirement portfolios. AbbVie's signal is described as widening with rising moving averages, whereas Baxter's is characterized as razor-thin and sitting atop a declining 200-day moving average.
Fundamentally, the divergence between the two companies is stark. AbbVie declared a quarterly dividend of $1.73, maintaining a 13-year streak of increases and offering a yield near 2.8% at its current price. In contrast, Baxter effectively eliminated its dividend to just $0.01 per share following poor financial results in FY2025, which included a net loss of $900 million.
AbbVie's growth is driven by its immunology franchise, where Skyrizi and Rinvoq revenues grew 31% and 23% respectively in Q1 2026, successfully offsetting the decline from Humira biosimilars. This strong performance prompted management to raise full-year adjusted EPS guidance to between $14.08 and $14.28, with a consensus price target of $265.50 above the current trading price.
Conversely, Baxter faces significant headwinds including negative earnings, goodwill impairments, and operational overhangs such as shipment holds and tariff pressures. With a new CEO recently appointed and analyst targets below the current stock price, the article positions AbbVie as the clear winner for investors seeking stability, income, and growth, while labeling Baxter a speculative turnaround play.
๐ AbbVie shows widening golden cross; Baxter sits on declining moving average.
๐ฐ AbbVie pays $1.73 quarterly dividend; Baxter slashed payout to $0.01.
๐ Baxter lost $900M net income; AbbVie holds $432.5B market cap.
๐ AbbVie's Skyrizi grew 30.9%; Rinvoq rose 23.3% in Q1 2026.
๐ฏ AbbVie target is $265.50; Baxter target trails current price.
๐ Technical Analysis: Both AbbVie and Baxter flashed a 'golden cross' signal, but AbbVie's is widening with rising averages while Baxter's sits atop a declining 200-day moving average.
๐ฐ Dividend Status: AbbVie declared a $1.73 quarterly payout (2.8% yield) extending a 13-year increase streak, whereas Baxter slashed its dividend to $0.01 per share.
๐ Financial Performance: Baxter posted a -$900 million net income in FY2025 due to goodwill and intangible impairments, while AbbVie maintains a $432.5 billion market cap and 26.6% operating margin.
๐ Growth Drivers: AbbVie's Skyrizi grew 30.9% and Rinvoq rose 23.3% in Q1 2026, more than offsetting Humira's biosimilar erosion.
๐ Guidance Update: Following the Q1 report, AbbVie raised its full-year adjusted EPS guidance to a range of $14.08 to $14.28.
๐ฏ Price Targets: The consensus price target for AbbVie is $265.50 compared to a recent close of $244.78, while Baxter's target is below its current price.
๐ Operational Risks: Baxter faces challenges including the Novum IQ LVP pump shipment hold, tariff pressure, and a reset following the Kidney Care sale.
๐ Stock History: AbbVie shares returned 27.8% over the past year, while Baxter shares are down 53.4% over the last decade.
๐ Leadership Change: Baxter appointed new CEO Andrew Hider in September 2025 to lead a turnaround and write a new operating model.
๐ Portfolio Fit: The article concludes AbbVie is the definitive choice for retirees needing income, while Baxter remains only suitable for deep-value investors with no need for dividends.
Bullish Signals
AbbVie declared a $1.73 quarterly dividend with an ex-dividend date of July 15, 2026.
Skyrizi revenue grew 30.9% to $4.48 billion and Rinvoq rose 23.3% to $2.12 billion.
Management raised full-year adjusted EPS guidance to $14.08-$14.28 following strong Q1 results.
The stock has returned 27.8% over the past year and 478.9% over 10 years.
Consensus price target of $265.50 is significantly higher than the current trading price of $244.78.
Risk Factors
$900M net loss driven by $485M goodwill and $290M intangible impairments.
Dividend slashed to $0.01, eliminating income for investors.
Negative book value from buybacks and Allergan-era leverage.
Operational issues: Novum IQ pump hold and tariff pressure.
$21.71 analyst target below current stock price.
Bullish Signals
AbbVie declared a $1.73 quarterly dividend with an ex-dividend date of July 15, 2026, extending a 13-year streak of annual increases.
Skyrizi revenue grew 30.9% to $4.48 billion and Rinvoq rose 23.3% to $2.12 billion in Q1 2026, offsetting Humira losses.
Management raised full-year adjusted EPS guidance to $14.08-$14.28 following strong Q1 results.
AbbVie maintains a low beta of 0.283, indicating roughly one-quarter of the market's volatility.
The stock has returned 27.8% over the past year and 478.9% over 10 years including reinvested momentum.
Consensus price target of $265.50 is significantly higher than the current trading price of $244.78.
Risk Factors
Baxter posted a -$900 million net income in FY2025 after recording $485 million in goodwill impairments and $290 million in intangible impairments.
Baxter's quarterly dividend was slashed to $0.01, effectively eliminating the payout for income-focused investors.
Baxter carries negative book value due to buybacks and Allergan-era leverage issues.
Baxter faces operational overhangs including a hold on Novum IQ LVP pump shipments and tariff pressure.
Analyst consensus price target for Baxter is $21.71, which is less than the current stock price.
Analyst H. Engel at Erste Group Bank lowered its full-year 2026 earnings per share (EPS) estimate for AbbVie to $14.08, down from a previous forecast of $14.23. This adjustment brings the analyst's projection slightly below the current market consensus of $14.16. The report was issued on July 15th, contributing to a mixed landscape of Wall Street sentiment regarding the biopharmaceutical giant.
Despite the downgrade from Erste Group, AbbVie maintains a 'Moderate Buy' average rating with an average price target of $267.67 according to MarketBeat data. The stock recently opened at $254.53, trading above its 50-day and 200-day moving averages. Recent analyst actions include Citigroup raising its price target to $260.00 with a neutral rating, while HSBC set a higher objective of $300.00.
The company reported strong first-quarter results on April 29th, beating consensus estimates with EPS of $2.65 and revenue of $15 billion, which represented a 12.4% year-over-year increase. Institutional ownership remains high at 70.23%, with several major firms like Calamos Advisors and Wealth Enhancement Advisory Services increasing their stakes in the fourth quarter.
AbbVie declared a quarterly dividend of $1.73 per share, payable on August 14th to shareholders of record as of July 15th. This represents an annualized yield of 2.7% based on a payout ratio of 340.89%. The company continues to focus on its diverse portfolio across immunology, oncology, and neuroscience, maintaining its position as a global research-driven biopharmaceutical entity.
๐ Erste Group cut FY2026 EPS forecast to $14.08 below consensus.
๐ Q1 earnings beat with $2.65 EPS and $15B revenue growth.
๐ฐ Quarterly dividend of $1.73 offers 2.7% annualized yield.
๐ Institutional investors increased holdings by over 3% in Q4.
๐ HSBC set $300 price target while sentiment remains mixed.
๐ Erste Group Bank analyst H. Engel cut FY2026 EPS estimates for AbbVie to $14.08 from $14.23, placing the forecast below the consensus of $14.16.
๐ The stock opened at $254.53 with a market cap of $449.70 billion and a PE ratio of 125.38, trading above its key moving averages.
๐ Q1 earnings beat consensus significantly with $2.65 EPS versus $2.59 expected and revenue reaching $15 billion, up 12.4% year-over-year.
๐ Major institutional investors including Calamos Advisors and Wealth Enhancement Advisory Services increased their holdings by over 3% in the fourth quarter.
๐ฐ AbbVie declared a quarterly dividend of $1.73 per share with an ex-dividend date of July 15th, offering a 2.7% annualized yield.
๐ Analyst sentiment remains mixed but generally positive, with HSBC setting a $300 price target and Guggenheim raising its objective to $261.
๐งฌ The company continues to expand its portfolio in immunology, oncology, neuroscience, virology, and women's health therapeutic areas.
๐ Wall Street Zen downgraded the stock from 'strong-buy' to 'buy', while Sanford C. Bernstein maintained a 'market perform' rating.
Bullish Signals
Q1 revenue hit $15B, beating estimates with 12.4% growth.
EPS reached $2.65, surpassing the $2.59 consensus target.
Major investors increased stakes, including Wealth Enhancement by 11.7%.
HSBC set a high price objective of $300.00.
Stock trades above 50-day ($229.80) and 200-day ($221.94) averages.
Risk Factors
Analyst lowered FY2026 EPS forecast to $14.08 below consensus.
Downgrade from strong-buy to buy reduces bullish sentiment.
High PE ratio of 125.38 suggests unsustainable growth pricing.
Bullish Signals
AbbVie reported Q1 revenue of $15 billion, surpassing analyst estimates of $14.72 billion and showing a robust 12.4% year-over-year growth.
The company beat Q1 earnings expectations with EPS of $2.65 compared to the consensus of $2.59, demonstrating strong operational performance.
Multiple major institutional investors increased their stakes in the fourth quarter, including Calamos Advisors raising holdings by 3.4% and Wealth Enhancement Advisory Services by 11.7%.
HSBC issued a high price objective of $300.00 for AbbVie shares, indicating strong long-term confidence from major financial institutions.
The stock trades above both its 50-day moving average ($229.80) and 200-day moving average ($221.94), suggesting positive short-to-medium term momentum.
AbbVie maintains a high institutional ownership of 70.23%, reflecting strong confidence from professional money managers in the company's future prospects.
Risk Factors
Erste Group Bank analyst H. Engel lowered its FY2026 EPS forecast to $14.08, which is below the current market consensus estimate of $14.16.
Wall Street Zen downgraded AbbVie from a 'strong-buy' rating to a 'buy' rating, indicating a reduction in immediate bullish sentiment.
The stock carries a very high PE ratio of 125.38, which may suggest the market is pricing in significant future growth that could be difficult to sustain.
AbbVie (ABBV) shares have risen 8.9% year-to-date as investors gain confidence in the company's post-Humira growth strategy. Despite the loss of exclusivity for its blockbuster drug Humira, which saw sales decline around 50% in 2025 due to biosimilar erosion, AbbVie has successfully offset this revenue with strong performance from its immunology portfolio, specifically Skyrizi and Rinvoq.
The company expects combined sales of Skyrizi and Rinvoq to exceed $31 billion in 2026, reflecting over 20% growth driven by new indications and market share gains. While the company anticipates low single-digit pricing headwinds and faces competition from Johnson & Johnson's new oral psoriasis drug Icotyde, AbbVie remains confident in navigating these challenges to support top-line expansion.
Beyond immunology, AbbVie is leveraging momentum in its neuroscience and oncology segments. The Parkinson's disease franchise, led by Vyalev, has a peak sales potential of over $5 billion, while the oncology pipeline remains robust despite slight slowing in Imbruvica sales. Strategic acquisitions, such as the $10.9 billion deal for Apogee Therapeutics, are further bolstering the late-stage pipeline.
From a valuation perspective, ABBV trades at a forward P/E of 16.07, which is lower than the industry average of 18.59 but above its five-year mean. Recent analyst estimates for 2026 and 2027 have declined slightly due to acquisition-related costs. While long-term investors may retain the stock given intact prospects, short-term investors might consider exiting as Zacks Rank #4 (Sell) ratings reflect these near-term estimate pressures.
๐ ABBV stock rose 31.5% over the past year outperforming industry trends.
๐ Skyrizi and Rinvoq expected to generate $31 billion in combined 2026 sales.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)